Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in France / NCT05486455
Recruiting Not applicable

Evaluation of Lung Cancer CT Screening Performance Among Former and Current Smokers

NCT05486455 · tracked via the Priya Life Science France tracker
Sponsor
Hospital St. Joseph, Marseille, France
Phase
Not applicable
Started
2022-11-04
Last updated
2022-12-06

Condition(s) studied

Smoking

Investigational drug(s) / intervention(s)

Low-dose chest CT scan

Low-dose chest CT scan: baseline, 1-year, 3-year and 5-year low-dose CT scan

Study summary

Diagnostic performance of low-dose chest CT scan combined with lung-RADS classification (version 1.1) for lung cancer screening among former and current smokers.

Eligibility

Sex
ALL
Min age
50 Years
Max age
80 Years
Healthy volunteers
No
Inclusion Criteria: * Male or female 50-80 years old * Active smoker (≥ 15 PA) or former smoker (≥ 15 PA) Exclusion Criteria: * Recent history of chest CT scan (within 12 months) * Person unable to climb 2 floors * Weight \> 140kg * Personal history of cancer \< 5 years (currently being monitored by thoracic imaging)

Primary outcome measure(s)

  • Positive Predictive Value (PPV) — 5 years

Trial sites (1)

FacilityCityRegionStatus
Hôpital Saint Joseph Marseille France Recruiting

More Hospital St. Joseph, Marseille, France trials in France

Interest of the Immunoscore® as a Post-operative Complementary Tool for the Detection of the Risk of Recurrence in Patients With Nonmetastatic Colorectal Cancer Recruiting
Feasibility of Molecular Biology in Pancreatic Cyst Tumors Active, not recruiting

Other trials for the same condition

Factors Sustaining Tobacco Abstinence in Cancer Patients Treated With Radio-chemotherapy or Radiotherapy Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05486455 on ClinicalTrials.gov ↗ ← All trials in France